INTS - Earnings announcements

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 StudyCash and cash equivalents of $9.5 million as of June 30, 2026Increased business development activitiesConference call begins at 8:00 a.m. Eastern time todaySHELTON, Conn., Aug. 11, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tum

Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate updateSHELTON, Conn., Aug. 4, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on August 11, 2026.

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety The manuscript is open access The Company will host a webinar with the paper's lead and senior authors from the University of Southern California to discuss the results on Friday, October 31, 2025, at 9:00 AM (see below) SHELTON, Conn., Oct. 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that